Searching News Database: Clobetasol
HSMN NewsFeed - 25 Apr 2018
Dermtreat Appoints Nishan de Silva, M.D., as CEO; Establishes North American Headquarters in San Diego
Dermtreat Appoints Nishan de Silva, M.D., as CEO; Establishes North American Headquarters in San Diego
HSMN NewsFeed - 16 Mar 2017
Sonoma Pharmaceuticals Announces Results from SebuDerm(TM) Gel Study in Treatment of Seborrheic Dermatitis
Sonoma Pharmaceuticals Announces Results from SebuDerm(TM) Gel Study in Treatment of Seborrheic Dermatitis
HSMN NewsFeed - 17 Dec 2015
Oculus Innovative Sciences Receives FDA Clearance for Microcyn(R)-Based SebDerm Gel
Oculus Innovative Sciences Receives FDA Clearance for Microcyn(R)-Based SebDerm Gel
HSMN NewsFeed - 28 Dec 2012
Perrigo Company Acquires Remaining Stake in Cobrek Pharmaceuticals, Inc. for Approximately $45 Million
Perrigo Company Acquires Remaining Stake in Cobrek Pharmaceuticals, Inc. for Approximately $45 Million
HSMN NewsFeed - 4 Jun 2012
Hi-Tech Pharmacal Acquires Rights to the Cormax(R) Brand for its ECR Pharmaceuticals Subsidiary
Hi-Tech Pharmacal Acquires Rights to the Cormax(R) Brand for its ECR Pharmaceuticals Subsidiary
HSMN NewsFeed - 21 Sep 2009
AZZALURE(R) approved in Spain for Aesthetic Use in the Treatment of Glabellar Lines
AZZALURE(R) approved in Spain for Aesthetic Use in the Treatment of Glabellar Lines
HSMN NewsFeed - 26 Jun 2009
AZZALURE(R) Approved in Germany for Aesthetic Use in the Treatment of Glabellar Lines
AZZALURE(R) Approved in Germany for Aesthetic Use in the Treatment of Glabellar Lines
HSMN NewsFeed - 31 Mar 2009
AZZALURE( )is Approved in France for Aesthetic Use in the Treatment of Frown Lines
AZZALURE( )is Approved in France for Aesthetic Use in the Treatment of Frown Lines
HSMN NewsFeed - 12 Mar 2009
Ipsen: AZZALURE Approved in the UK for Aesthetic Use in the Treatment of Glabellar Lines
Ipsen: AZZALURE Approved in the UK for Aesthetic Use in the Treatment of Glabellar Lines
HSMN NewsFeed - 8 Jul 2008
Stiefel Laboratories, Inc. Commences Tender Offer to Acquire Barrier Therapeutics, Inc.
Stiefel Laboratories, Inc. Commences Tender Offer to Acquire Barrier Therapeutics, Inc.
HSMN NewsFeed - 23 Jun 2008
Barrier Therapeutics, Inc. and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
Barrier Therapeutics, Inc. and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
HSMN NewsFeed - 23 Apr 2007
Stiefel Laboratories Moves to Solidify, Enhance Its Leadership Position in Dermatology
Stiefel Laboratories Moves to Solidify, Enhance Its Leadership Position in Dermatology
HSMN NewsFeed - 23 Oct 2006
Connetics Corporation and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
Connetics Corporation and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
HSMN NewsFeed - 19 Sep 2006
FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to-Moderate Atopic Dermatitis
FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to-Moderate Atopic Dermatitis
HSMN NewsFeed - 8 May 2006
Connetics Names Sunil Patel Vice President, Corporate Development and Strategy
Connetics Names Sunil Patel Vice President, Corporate Development and Strategy
Additional items found! 33
Members Archive contains
33 additional stories matching:
Clobetasol
(Password required)
Clobetasol
(Password required)
